Icon Advisers’s ANI Pharmaceuticals ANIP Stock Holding History

Icon Advisers’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-8,700	Closed	-$407K	–	385
2017 Q2	$407K	Sell	8,700 -12,000	-58%	-$579K	0.03%	352
2017 Q1	$1.02M	Buy	+20,700	New	+$1.16M	0.07%	280
2015 Q2	–	Sell	-7,092	Closed	-$444K	–	335
2015 Q1	$444K	Buy	+7,092	New	+$431K	0.03%	315

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Icon Advisers's ANIP Position: Q3 2017 in Review

Icon Advisers sold out of ANI Pharmaceuticals (ANIP) in Q3 2017, closing a stake of 8,700 shares — an estimated $407K sold.

Icon Advisers first reported a position in ANIP in Q1 2015 and held it in 3 quarters. The position peaked at $1.02M in Q1 2017. 146 funds tracked by Wall St. Rank hold ANIP as of Q3 2017.

Icon Advisers reported no remaining ANI Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Icon Advisers sold 8,700 ANI Pharmaceuticals shares in Q3 2017, an estimated $407K.
Icon Advisers first reported a position in ANI Pharmaceuticals in Q1 2015 and held it in 3 quarters.
Icon Advisers's ANI Pharmaceuticals position peaked at $1.02M in Q1 2017.
146 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2017.

Based on Icon Advisers's 13F filing for Q3 2017, filed 8 Nov 2017.